HYDROXYCHLOROQUINE ( DrugBank: Hydroxychloroquine )

---

27 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	3
34	神経線維腫症	1
41	巨細胞性動脈炎	1
43	顕微鏡的多発血管炎	2
44	多発血管炎性肉芽腫症	2
45	好酸球性多発血管炎性肉芽腫症	2
46	悪性関節リウマチ	42
48	原発性抗リン脂質抗体症候群	2
49	全身性エリテマトーデス	20
53	シェーグレン症候群	18
56	ベーチェット病	1
63	特発性血小板減少性紫斑病	1
66	IgA腎症	6
84	サルコイドーシス	3
89	リンパ脈管筋腫症	1
90	網膜色素変性症	1
96	クローン病	2
97	潰瘍性大腸炎	1
107	若年性特発性関節炎	1
218	アルポート症候群	2
222	一次性ネフローゼ症候群	2
224	紫斑病性腎炎	2
234	ペルオキシソーム病（副腎白質ジストロフィーを除く。）	1
254	ポルフィリン症	1
271	強直性脊椎炎	1
298	遺伝性膵炎	1
299	嚢胞性線維症	1

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2022-003170-23-FI (EUCTR)	20/12/2022	30/09/2022	Hydroxychloroquine in progressive MS	Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral hydroxychloroquine 200 mg BID for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)	Progressive multiple sclerosis MedDRA version: 21.1;Level: PT;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Oxiklorin Product Name: Oxiklorin INN or Proposed INN: Hydroxychloroquine sulfate	Varsinais-Suomen sairaanhoitopiirin kuntayhtymä	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Finland
2	NCT05013463 (ClinicalTrials.gov)	October 1, 2021	16/8/2021	Hydroxychloroquine and Indapamide in SPMS	Open-label, Single-center, Single-arm Futility Trial Evaluating the Combination of Oral Hydroxychloroquine 200mg BID and Indapamide 2.5mg OD for Reducing Progression of Disability in People With Secondary Progressive Multiple Sclerosis (SPMS)	Multiple Sclerosis, Secondary Progressive	Drug: Hydroxychloroquine Pill;Drug: Indapamide Pill	University of Calgary	NULL	Recruiting	18 Years	60 Years	All	35	Phase 2	Canada
3	NCT02913157 (ClinicalTrials.gov)	November 2016	20/9/2016	Hydroxychloroquine in Primary Progressive Multiple Sclerosis	Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)	Multiple Sclerosis, Primary Progressive	Drug: Hydroxychloroquine	University of Calgary	NULL	Completed	18 Years	65 Years	All	35	Phase 2	Canada

34. 神経線維腫症

---

臨床試験数 : 133 /  薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04201457 (ClinicalTrials.gov)	January 17, 2020	12/12/2019	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults	Low Grade Glioma (LGG) of Brain With BRAF Aberration;High Grade Glioma (HGG) of the Brain With BRAF Aberration;Low Grade Glioma of Brain With Neurofibromatosis Type 1	Drug: Dabrafenib;Drug: Trametinib;Drug: Hydroxychloroquine	Pediatric Brain Tumor Consortium	NULL	Recruiting	1 Year	30 Years	All	75	Phase 1/Phase 2	United States

41. 巨細胞性動脈炎

---

臨床試験数 : 131 /  薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 125

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00430807 (ClinicalTrials.gov)	January 2002	31/1/2007	Hydroxychloroquine in Giant Cell Arteritis	Multicentric Double Blind Versus Placebo Randomised Study Evaluating the Corticosteroid Sparing Effect of Hydrocyschloroquine in Non Complicated Giant Cell Arteritis.	Giant Cell Arteritis	Drug: hydroxychloroquine/placebo	University Hospital, Toulouse	NULL	Completed	18 Years	85 Years	Both	75	Phase 3	France

43. 顕微鏡的多発血管炎

---

臨床試験数 : 88 /  薬物数 : 81 - (DrugBank : 21) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 90

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04316494 (ClinicalTrials.gov)	December 17, 2020	25/2/2020	Hydroxychloroquine in ANCA Vasculitis Evaluation	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial	ANCA Associated Vasculitis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Wegener Granulomatosis	Drug: Hydroxychloroquine;Drug: Placebo	Guy's and St Thomas' NHS Foundation Trust	Medical Research Council	Recruiting	18 Years	N/A	All	76	Phase 4	United Kingdom
2	EUCTR2018-001268-40-GB (EUCTR)	23/01/2020	13/09/2019	Hydroxychloroquine in ANCA vasculitis	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - HAVEN	The term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). AAV are serious multisystem autoimmune disorders that can affect any organ in the body and commonly involve the ear-nose-throat, lungs, kidneys, eyes and joints MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Plaquenil - Hydroxychloroquine 200mg Film coated tablets	Guy's and St. Thomas' NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	76	Phase 4	United Kingdom

44. 多発血管炎性肉芽腫症

---

臨床試験数 : 98 /  薬物数 : 108 - (DrugBank : 28) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 81

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04316494 (ClinicalTrials.gov)	December 17, 2020	25/2/2020	Hydroxychloroquine in ANCA Vasculitis Evaluation	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial	ANCA Associated Vasculitis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Wegener Granulomatosis	Drug: Hydroxychloroquine;Drug: Placebo	Guy's and St Thomas' NHS Foundation Trust	Medical Research Council	Recruiting	18 Years	N/A	All	76	Phase 4	United Kingdom
2	EUCTR2018-001268-40-GB (EUCTR)	23/01/2020	13/09/2019	Hydroxychloroquine in ANCA vasculitis	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - HAVEN	The term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). AAV are serious multisystem autoimmune disorders that can affect any organ in the body and commonly involve the ear-nose-throat, lungs, kidneys, eyes and joints MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Plaquenil - Hydroxychloroquine 200mg Film coated tablets	Guy's and St. Thomas' NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	76	Phase 4	United Kingdom

45. 好酸球性多発血管炎性肉芽腫症

---

臨床試験数 : 31 /  薬物数 : 44 - (DrugBank : 18) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 101

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04316494 (ClinicalTrials.gov)	December 17, 2020	25/2/2020	Hydroxychloroquine in ANCA Vasculitis Evaluation	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial	ANCA Associated Vasculitis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Wegener Granulomatosis	Drug: Hydroxychloroquine;Drug: Placebo	Guy's and St Thomas' NHS Foundation Trust	Medical Research Council	Recruiting	18 Years	N/A	All	76	Phase 4	United Kingdom
2	EUCTR2018-001268-40-GB (EUCTR)	23/01/2020	13/09/2019	Hydroxychloroquine in ANCA vasculitis	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - HAVEN	The term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). AAV are serious multisystem autoimmune disorders that can affect any organ in the body and commonly involve the ear-nose-throat, lungs, kidneys, eyes and joints MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Plaquenil - Hydroxychloroquine 200mg Film coated tablets	Guy's and St. Thomas' NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	76	Phase 4	United Kingdom

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05626348 (ClinicalTrials.gov)	December 22, 2021	15/11/2022	The Clinical Efficacy of Immunomodulators in RA Patients	The Clinical Study to Observe the Efficacy and Safety of Immunomodulators in Rheumatoid Arthritis Patients for 6 Months Treatment in China	Arthritis, Rheumatoid	Drug: Iguratimod;Drug: Methotrexate;Drug: Adalimumab Injection;Drug: Leflunomide;Drug: Hydroxychloroquine	Qilu Hospital of Shandong University	NULL	Recruiting	18 Years	80 Years	All	400	Phase 4	China
2	NCT05651373 (ClinicalTrials.gov)	July 30, 2021	15/11/2022	The Clinical Features and Pregnancy Outcomes of RA Patients	The Clinical Features and Pregnancy Outcomes of Patients With Rheumatoid Arthritis :a Prospective Cohort Study	Rheumatoid Arthritis;Pregnancy Related	Drug: Prednisone;Drug: Hydroxychloroquine;Drug: CertolizumabPegol injection	Qilu Hospital of Shandong University	NULL	Recruiting	20 Years	45 Years	Female	100		China
3	ChiCTR2100048802	2021-07-15	2021-07-16	A prospective non-randomized controlled study on the treatment of interstitial pneumonia of RA with Peitushengjinjiedutongluo method	A prospective cohort study on the treatment of interstitial pneumonia of RA with Peitushengjinjiedutongluo method	Rheumatoid arthritis with interstitial pneumonia	experimental group:Syndrome Differentiation and Flavoring of Peitushengjin Chinese Medicine Granules;control group:Hydroxychloroquine + prednisone;	Zhejiang Chinese Medical University	NULL	Pending	18	65	Both	experimental group:285;control group:240;	N/A	China
4	ITMCTR2100005066	2021-07-15	2021-07-16	A prospective non-randomized controlled study on the treatment of interstitial pneumonia of RA with Peitushengjinjiedutongluo method	A prospective cohort study on the treatment of interstitial pneumonia of RA with Peitushengjinjiedutongluo method	Rheumatoid arthritis with interstitial pneumonia	control group:Hydroxychloroquine + prednisone;experimental group:Syndrome Differentiation and Flavoring of Peitushengjin Chinese Medicine Granules;	Zhejiang Chinese Medical University	NULL	Pending	18	65	Both	control group:240;experimental group:285;	N/A	China
5	NCT04691505 (ClinicalTrials.gov)	December 23, 2020	28/12/2020	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Methotrexate vs Hydroxychloroquine	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Hydroxychloroquine	Brigham and Women's Hospital	National Institute on Aging (NIA);Rutgers University;Johns Hopkins University	Completed	18 Years	N/A	All	133553		United States
6	NCT04569890 (ClinicalTrials.gov)	December 1, 2020	20/9/2020	Treatment of Pregnancy RA	Study on the Treatment Strategy of Patients With Rheumatoid Arthritis During Pregnancy, a Randomized Control Trial in China	Rheumatoid Arthritis;Pregnancy Related	Drug: Certolizumab Pegol 200 MG/ML [Cimzia];Drug: Hydroxychloroquine;Drug: Prednisone	RenJi Hospital	NULL	Not yet recruiting	20 Years	40 Years	Female	100	N/A	China
7	NCT04389320 (ClinicalTrials.gov)	March 15, 2020	11/5/2020	Antimalarial and Covid 19 in Rheumatoid Arthritis	Antimalarial and Covid 19 in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Hydroxychloroquine	Assiut University	NULL	Completed	20 Years	70 Years	All	60		Egypt
8	ChiCTR2000032534	2019-05-15	2020-05-01	Pharmacoeconomic evaluation of Anbainuo in the treatment of moderate to severe rheumatoid arthritis - a single center, control study	Pharmacoeconomic evaluation of Anbainuo in the treatment of moderate to severe rheumatoid arthritis - a single center, control study	Rheumatoid arthritis	Experimental group:Anbainuo plus methotrexate;Control group:Methotrexate, salazopyridine, leflumide, hydroxychloroquine;	The Affiliated ZhuZhou Hospital Of XiangYa School Of Medicine CSU.	NULL	Completed			Both	Experimental group:47;Control group:43;	Phase 4	China
9	NCT03813771 (ClinicalTrials.gov)	March 2019	12/9/2018	Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification	Targeted Treatment Early With Etanercept Plus Methotrexate Versus T2T Care for DMARD-naïve Early RA Patients. A Prospective, Longitudinal Cohort Study With Embedded Pilot Randomised Controlled Trial to Assess Treatment Rationalisation Based on naïve T-cell Stratification.	Rheumatoid Arthritis	Drug: Benepali;Drug: Sulfasalazine;Drug: Methotrexate;Drug: Hydroxychloroquine	University of Leeds	Samsung Bioepis Co., Ltd.	Not yet recruiting	18 Years	N/A	All	106	Phase 4	United Kingdom
10	EUCTR2017-004543-20-ES (EUCTR)	22/01/2019	25/10/2018	EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA).	EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA). - PALABA	PALINDROMIC RHEUMATISM;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: ORENCIA INN or Proposed INN: ABATACEPT Trade Name: Dolquine INN or Proposed INN: HYDROXYCHLOROQUINE	Fundació Clínic per a la Recerca Biomèdica	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	98	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Spain
11	NCT03449758 (ClinicalTrials.gov)	March 5, 2018	8/2/2018	Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis	Effect of Sarilumab on Patient-reported Outcomes in Patients With Moderately to Severely Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors	Rheumatoid Arthritis	Drug: SARILUMAB;Drug: Azathioprine;Drug: Chloroquine;Drug: Hydroxychloroquine;Drug: Leflunomide;Drug: Methotrexate;Drug: Sulfasalazine	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	84	Phase 4	France
12	JPRN-jRCTs031180050	26/12/2017	07/12/2018	Hydroxychloroquine for Japanese patients with rheumatoid arthritis	Efficacy and safety of hydroxychloroquine for Japanese patients with rheumatoid arthritis	Rheumatoid arthritis;D001172	Treatment with hydroxychloroquine for 24 weeks	Kaneko Yuko	NULL	Not Recruiting	>= 18age old	Not applicable	Both	120	Phase 2-3	Japan
13	NCT03085940 (ClinicalTrials.gov)	January 20, 2017	7/2/2017	Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis	Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Hydroxychloroquine;Drug: Placebo	Indonesia University	NULL	Completed	18 Years	N/A	All	37	N/A	Indonesia
14	NCT02930343 (ClinicalTrials.gov)	September 2016	13/9/2016	Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy	Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Randomized Control Trial	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Leflunomide;Drug: Hydroxychloroquine;Drug: Prednisolone;Drug: Folic Acid;Drug: Sulfasalazine	Jawaharlal Institute of Postgraduate Medical Education & Research	NULL	Terminated	18 Years	65 Years	All	136	Phase 3	India
15	NCT02603146 (ClinicalTrials.gov)	April 27, 2016	10/11/2015	Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis	Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis	Healthy Participants;Rheumatoid Arthritis (RA) Prevention	Drug: Hydroxychloroquine;Drug: HCQ Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Completed	18 Years	N/A	All	144	Phase 2	United States
16	NCT02644499 (ClinicalTrials.gov)	December 31, 2015	30/12/2015	Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis	Comparison of Combination Disease Modifying Antirheumatic Drugs (DMARDs) With Single Drug (Methotrexate) Therapy in Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Leflunomide;Drug: Hydroxychloroquine;Drug: Prednisolone;Drug: Folic Acid	Jawaharlal Institute of Postgraduate Medical Education & Research	NULL	Completed	18 Years	N/A	All	186	Phase 4	India
17	NCT02320630 (ClinicalTrials.gov)	October 2015	16/12/2014	Combination Therapy Prevents the Relapse of RA	The Efficacy, Safety and Cost-effectiveness of Hydroxychloroquine, Sulfasalazine, Methotrexate Triple Therapy in Preventing Relapse Among Patients With Rheumatoid Arthritis Achieving Clinical Remission or Low Disease Activity	Recurrence (Disease Attribute)	Drug: Entanercept;Drug: HCQ;Drug: MTX	Peking University First Hospital	Peking University People's Hospital;Peking University Third Hospital;Beijing Hospital;Beijing Jishuitan Hospital;Peking University Shougang Hospital;Beijing Shijitan Hospital	Recruiting	18 Years	70 Years	All	240	N/A	China
18	NCT02451748 (ClinicalTrials.gov)	August 2015	6/5/2015	IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA	IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA	Rheumatoid Arthritis	Other: Lab Work;Drug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg);Drug: Certolizumab pegol (CDP870, tradename Cimzia);Drug: Hydroxychloroquine;Drug: Sulfasalazine;Drug: Medrol;Drug: Prednisone;Drug: Triamcinolone;Drug: Naproxen;Drug: Leflunomide;Drug: Methotrexate;Drug: humira	University of Illinois at Chicago	UCB Pharma	Completed	18 Years	N/A	All	32	Phase 4	United States
19	EUCTR2011-004720-35-NO (EUCTR)	04/05/2015	26/01/2015	A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.	A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment. - NORD-STAR	Rheumatoid arthritis (RA) MedDRA version: 18.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia INN or Proposed INN: CERTOLIZUMAB PEGOL Trade Name: Orencia INN or Proposed INN: ABATACEPT Trade Name: RoActemra Other descriptive name: TOCILIZUMAB Trade Name: Methotrexate INN or Proposed INN: METHOTREXATE Trade Name: Metex INN or Proposed INN: METHOTREXATE Other descriptive name: METHOTREXATE DISODIUM Trade Name: Imurel INN or Proposed INN: IMUREL Other descriptive name: AZATHIOPRINE Trade Name: Arava INN or Proposed INN: LEFLUNOMIDE Other descriptive name: Arava Product Name: Salazopyrin EN INN or Proposed INN: Salazopyrin EN Other descriptive name: SULFASALAZINE Trade Name: Plaquenil Product Name: Plaquenil INN or Proposed INN: Plaquenil Other descriptive name: HYDROXYCHLOROQUINE SULFATE	Karolinska Institutet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	800	Phase 4	Finland;Denmark;Norway;Sweden
20	EUCTR2014-005418-45-SE (EUCTR)	04/05/2015	18/03/2015	Are risk factors factors of pertaining to or involving the heart and blood vessels and markers characterized or caused by inflammation in Rheumatoid Arthritis (a chronic, systemic inflammatory disorder that primarily affects joints) and Systemic Lupus Erythematosus (systemic disease in which the body’s immune system mistakenly attacks healthy tissue)improved? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE)	Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE) - HCQCVDRASLE	Rheumatoid Arthritis and Systemic Lupus Erythematosus;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Plaquenil INN or Proposed INN: HYDROXYCHLOROQUINE	Christine Bengtsson	Solveig Wållberg-Jonsson	Not Recruiting			Female: yes Male: yes		Phase 2	Sweden
21	EUCTR2011-004720-35-FI (EUCTR)	10/09/2014	09/09/2014	A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.	A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment. - NORD-STAR	Rheumatoid arthritis (RA) MedDRA version: 17.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia INN or Proposed INN: CERTOLIZUMAB PEGOL Trade Name: Orencia INN or Proposed INN: ABATACEPT Trade Name: RoActemra Other descriptive name: TOCILIZUMAB INN or Proposed INN: METHOTREXATE Trade Name: Metoject Other descriptive name: METHOTREXATE DISODIUM Other descriptive name: AZATHIOPRINE INN or Proposed INN: LEFLUNOMIDE Other descriptive name: Arava Product Name: Salazopyrin EN Other descriptive name: SULFASALAZINE Trade Name: Oxiklorin Product Code: 118-42-3 Other descriptive name: HYDROXYCHLOROQUINE SULFATE	Karolinska Institutet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 4	Finland;Denmark;Sweden
22	ChiCTR1900026116	2014-06-01	2019-09-22	The efficacy and safety of low-dose glucocorticoids combined withmethotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: a randomized, double-blinded, controlled trial	The efficacy and safety of low-dose glucocorticoids combined withmethotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: a randomized, double-blinded, controlled trial	rheumatoid arthritis	Experimental group:Prednisone+methotrexate+Hydrochloroquine;control group:placebo+methotrexate+Hydrochloroquine;	Central Hospital of Jinhua	NULL	Completed	21	73	Both	Experimental group:40;control group:40;	Phase 4	China
23	ChiCTR-TRC-14004520	2014-05-01	2014-04-13	To study the signal pathways of Rheumatoid Arthritis Syndrome of Accumulated Dampness and intervention mechanism of Sanhuang Yilong Decoction based the theory that lung, spleen and kidney regulate water	To study the signal pathways of Rheumatoid Arthritis Syndrome of Accumulated Dampness and intervention mechanism of Sanhuang Yilong Decoction based the theory that lung, spleen and kidney regulate water metabolism	rheumatoid arthritis	two:Methotrexate, hydroxychloroquine sulfate pills and NSAIDs in both groups; Sanhuang Yinong decoction will be give in the experimental group;RA patients:NA;	General Hospital of Chengdu Military Region	NULL	Recruiting	45	65	Both	two:240;RA patients:40;	I (Phase 1 study)	China
24	NCT02057250 (ClinicalTrials.gov)	March 2014	31/1/2014	To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who Are Candidates For Anti-IL6R Therapy	RA	Drug: Sarilumab;Device: Auto-Injector Device (AID);Device: Pre-filled Syringe (PFS);Drug: Methotrexate;Drug: Sulfasalazine;Drug: Leflunomide;Drug: Hydroxychloroquine	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	217	Phase 3	United States;Chile;Mexico;Poland;Russian Federation;South Africa;France
25	NCT01941095 (ClinicalTrials.gov)	November 20, 2013	30/8/2013	A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis	Multicenter, Open Label, Phase IIIb Study to Evaluate the Safety and Tolerability of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Methotrexate or Other Non-Biologic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Azathioprine;Drug: Chloroquine;Drug: Hydroxychloroquine;Drug: Leflunomide;Drug: Methotrexate;Drug: Sulfasalazine;Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	100	Phase 3	Greece
26	EUCTR2013-003658-26-NL (EUCTR)	13/11/2013	18/10/2013	Individualised treatment strategy based on disease activity for early RA patients in usual clinical practice: The COBRA Cohort Study	Treat-to-target strategy for early RA patients in usual clinical practice: The COBRA Cohort Study - COBRA Cohort Study	Early Active Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Methotrexate Product Name: Methotrexate INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Trade Name: Prednison Product Name: Prednison INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Plaquenil Product Name: hydroxycholoquine INN or Proposed INN: hydroxychloroquine sulfate Other descriptive name: HYDROXYCHLOROQUINE SULFATE Trade Name: Sulfasalazine Product Name: Sulfasalazine INN or Proposed INN: Sulfasalazine Other descriptive name: SULFASALAZINE	VU University Medical Center	NULL	Not Recruiting			Female: yes Male: yes	120	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Netherlands
27	NCT01768572 (ClinicalTrials.gov)	March 2013	11/1/2013	To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)	A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF Antagonists	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: tocilizumab;Drug: hydroxychloroquine;Drug: methotrexate;Drug: sulfasalazine;Drug: leflunomide;Drug: subcutaneous placebo;Drug: intravenous placebo	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	202	Phase 3	United States;Argentina;Belgium;Brazil;Czechia;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;Czech Republic
28	NCT01709578 (ClinicalTrials.gov)	October 2012	15/10/2012	To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)	A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-a Antagonists	Rheumatoid Arthritis	Drug: Sarilumab;Drug: placebo;Drug: hydroxychloroquine;Drug: methotrexate;Drug: sulfasalazine;Drug: leflunomide	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	546	Phase 3	United States;Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czechia;Ecuador;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;Czech Republic;Hong Kong
29	NCT02433184 (ClinicalTrials.gov)	July 2011	23/4/2015	Very Early Versus Delayed Etanercept in Patients With RA	A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early Versus Delayed Etanercept in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine	University of Leeds	NULL	Completed	18 Years	80 Years	All	120	Phase 4	United Kingdom
30	NCT01132118 (ClinicalTrials.gov)	June 2010	25/5/2010	Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis	Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis	Rheumatoid Arthritis;Insulin Resistance	Drug: Hydroxychloroquine	Brigham and Women's Hospital	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	N/A	All	30	Phase 3	United States
31	EUCTR2009-015740-42-DE (EUCTR)	12/05/2010	12/01/2010	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSIONRETRO – REduction of Therapy in RA patients in Ongoing remission,Reduzierung der Therapie bei RA-Patienten in Remission - RETRO	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSIONRETRO – REduction of Therapy in RA patients in Ongoing remission,Reduzierung der Therapie bei RA-Patienten in Remission - RETRO	Rheumatoid arthritis MedDRA version: 17.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Product Name: Prednisolon Product Code: Prednisolon INN or Proposed INN: PREDNISOLONE Trade Name: Humira INN or Proposed INN: ADALIMUMAB Product Name: Azathioprin Other descriptive name: AZATHIOPRINE Trade Name: Immunosporin Product Name: Immunosporin INN or Proposed INN: CICLOSPORIN Trade Name: Cimzia Product Name: Cimzia INN or Proposed INN: GOLIMUMAB Trade Name: Enbrel Product Name: Enbrel INN or Proposed INN: ETANERCEPT Product Name: Quensyl Other descriptive name: HYDROXYCHLOROQUINE SULFATE Trade Name: REMICADE Product Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Lantarel Product Name: Lantarel INN or Proposed INN: METHOTREXATE SODIUM Other descriptive name: Lantarel Trade Name: Arava Product Name: Arava INN or Proposed INN: LEFLUNOMIDE Other descriptive name: A	Universitätsklinkum Erlangen	NULL	Not Recruiting			Female: yes Male: yes	318	Phase 3	Germany
32	ChiCTR2100043373	2009-07-01	2021-02-12	Clinical study of Hydroxychloroquine Sulfate and sulfasalazine in the treatment of active rheumatoid arthritis	Clinical study of Hydroxychloroquine Sulfate and sulfasalazine in the treatment of active rheumatoid arthritis	rheumatoid arthritis	group one:HCQ(200mg/d)+MTX;group two:HCQ(400mg/d)+MTX;group three:HCQ(200mg/d)+SASP+MTX;group four:SASP+MTX;	Renji Hospital, Shanghai Jiaotong University School of Medicine	NULL	Completed			Both	group one:50;group two:50;group three:50;group four:50;	Phase 4	china
33	NCT03414502 (ClinicalTrials.gov)	August 2007	2/1/2014	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Abatacept;Drug: Adalimumab;Drug: Azathioprine;Drug: Baricitinib;Drug: Certolizumab;Drug: Etanercept;Drug: Golimumab;Drug: Hydroxychloroquine;Drug: Infliximab;Drug: Leflunomide;Drug: Minocycline;Drug: Rituximab;Drug: Sarilumab;Drug: Sulfasalazine;Drug: Tofacitinib	University of Nebraska	NULL	Recruiting	19 Years	N/A	All	400	Phase 3	United States
34	NCT00405275 (ClinicalTrials.gov)	July 2007	29/11/2006	Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy	CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Etanercept;Drug: methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine;Drug: Placebo, triple;Drug: Placebo, etanercept	VA Office of Research and Development	Canadian Institutes of Health Research (CIHR);Rheumatoid Arthritis Investigational Network (RAIN);National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	N/A	All	353	N/A	United States;Canada
35	NCT00422227 (ClinicalTrials.gov)	June 2007	11/1/2007	Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region	A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept , Methotrexate;Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	70 Years	All	300	Phase 4	Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand
36	EUCTR2007-001190-28-GB (EUCTR)	09/05/2007	17/04/2007	Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACIT	Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACIT	Rheumatoid Arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis	Product Name: Methotrexate Product Code: Methotrexate INN or Proposed INN: METHOTREXATE Product Name: Sulfasalazine Product Code: Sulfasalazine INN or Proposed INN: SULFASALAZINE Product Name: Hydroxychloroquine Product Code: Hydroxychloroquine INN or Proposed INN: Hydroxychloroquine Product Name: Ciclosporin Product Code: Ciclosporin INN or Proposed INN: Ciclosporin Product Name: Leflunomide Product Code: Leflunomide INN or Proposed INN: Leflunomide Product Name: Sodium aurothiomalate (intramuscular gold) Product Code: Sodium aurothiomalate (intramuscular gold) INN or Proposed INN: Sodium aurothiomalate Product Name: methylprednisolone Product Code: methylprednisolone INN or Proposed INN: Methylprednisolone Product Name: Prednisolone Product Code: Predniso	King's College London	NULL	Not Recruiting			Female: yes Male: yes	190	Phase 4	United Kingdom
37	EUCTR2006-006186-16-NL (EUCTR)	30/01/2007	16/07/2007	IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic DiseaseA randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent - IMPROVED	IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic DiseaseA randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent - IMPROVED	rheumatoid arthritis and undifferentiated arthritis MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis	Product Name: Methotrexate Product Code: MTX INN or Proposed INN: METHOTREXATE Product Name: Prednisone INN or Proposed INN: PREDNISONE Product Name: Sulfasalazine INN or Proposed INN: SULFASALAZINE Trade Name: hydroxychloroquine Product Name: hydroxychloroquine Product Code: HCQ INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE Trade Name: Humira Product Name: adalimumab	Leiden University Medical Center, department of rheumatology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
38	NCT05051137 (ClinicalTrials.gov)	January 12, 2006	10/9/2021	Real-World Emulation of the SWEFOT Trial	Comparison of Infliximab With Sulfasalazine/Hydroxychloroquine Initiated After Methotrexate by Rheumatoid Arthritis Patients Treated in Clinical Practice (Real-World Emulation of SWEFOT Trial)	Rheumatoid Arthritis	Biological: Infliximab;Drug: Sulfasalazine + Hydroxychloroquine	Karolinska Institutet	Harvard Medical School	Completed	18 Years	N/A	All	509		Sweden
39	EUCTR2004-002006-30-GB (EUCTR)	17/11/2004	17/02/2005	Triple therapy in early active rheumatoid arthritis - TEAR	Triple therapy in early active rheumatoid arthritis - TEAR	Rheumatoid arthritis	Product Name: Methotrexate INN or Proposed INN: Methotrexate Trade Name: Salazopyrin En-Tabs Product Name: sulfasalazine INN or Proposed INN: Sulfasalazine Trade Name: Plaquenil Product Name: Hydroxychloroquine INN or Proposed INN: Hydroxychloroquine	North Glasgow NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	96		United Kingdom
40	NCT00089921 (ClinicalTrials.gov)	July 2004	17/8/2004	SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine	Arthritis, Rheumatoid	Drug: SCIO-469;Drug: Placebo	Scios, Inc.	NULL	Completed	18 Years	N/A	Both	302	Phase 2	United States
41	NCT00259610 (ClinicalTrials.gov)	May 2004	28/11/2005	Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)	Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)	Rheumatoid Arthritis	Drug: methotrexate;Drug: sulfasalazine;Drug: hydroxychloroquine;Drug: etanercept	University of Alabama at Birmingham	Amgen;Barr Laboratories;Pfizer	Completed	18 Years	N/A	All	755	Phase 4	United States
42	NCT00579878 (ClinicalTrials.gov)	December 1999	17/12/2007	Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis	Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations (Leflunomide-Hydroxychloroquine-Sulfasalazine or Methotrexate-Hydroxychloroquine-Sulfasalazine) in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Leflunomide;Drug: Methotrexate-Sulfasalazine-Hydroxychloroquine;Drug: Leflunomide-Sulfasalazine-Hydroxychloroquine	University of Nebraska	NULL	Completed	19 Years	80 Years	All	69	Phase 3	United States

先頭へ

48. 原発性抗リン脂質抗体症候群

---

臨床試験数 : 5 /  薬物数 : 6 - (DrugBank : 4) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 7

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03540810 (ClinicalTrials.gov)	August 15, 2018	27/4/2018	Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome	Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome	Primary Antiphospholipid Syndrome	Drug: Hydroxychloroquine;Drug: Placebo	University Hospital, Angers	NULL	Not yet recruiting	18 Years	N/A	All	300	Phase 3	France
2	NCT04153201 (ClinicalTrials.gov)	January 15, 2013	21/10/2019	Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome	Effect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Patients With Primary Antiphospholipid Syndrome: An Pilot Randomized Prospective Study.	Antiphospholipid Syndrome	Drug: Hydroxychloroquine	National and Kapodistrian University of Athens	NULL	Completed	18 Years	N/A	All	50	N/A	Greece

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05666336 (ClinicalTrials.gov)	December 31, 2022	8/12/2022	Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients	Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Biological: Telitacicept;Drug: Hydroxychloroquine;Drug: Prednisone;Drug: Methylprednisolone;Drug: Cyclophosphamide;Drug: Mycophenolate Mofetil;Drug: Tacrolimus	Fen Li	NULL	Not yet recruiting	18 Years	75 Years	All	30	Phase 4	NULL
2	JPRN-jRCTs021210042	14/10/2021	14/10/2021	Randomized , double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab for early systemic lupus erythematosus	Randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab for early systemic lupus erythematosus - BEFORE-S	Systemic Lupus Erythematosus : SLE Systemic Lupus Erythematosus, SLE;D008180	Group A to which the test drug is administered and Group B to which the placebo is administered will be set. Group A: In addition to the usual treatment, belimumab (GlaxoSmithKline Co., Ltd., trade name Benlysta) will be administered subcutaneously once a week at 200 mg. Administration will be continued for 24 weeks. Group B: Placebo will be administered and standard of care will be performed. Both groups will receive a combination of hydroxychloroquine unless there is a reason not to use hydroxychloroquine as usual treatment. If the attending physician determines that it is not appropriate to administer the study drug, the attending physician will not administer the study drug during the week and will record the reason	Ishii Tomonori	NULL	Recruiting	>= 20age old	< 80age old	Both	30	N/A	Japan
3	ChiCTR2100048796	2021-07-15	2021-07-16	A prospective non-randomized controlled study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus	A prospective cohort study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus	Systemic lupus erythematosus	Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome differentiation;Control Group:Western Medicine (glucocorticoid, hydroxychloroquine, methotrexate, azathioprine or cyclophosphamide);	Zhejiang Chinese Medical University	NULL	Pending	18	65	Female	Experimental group:264;Control Group:264;	N/A	China
4	ITMCTR2100005063	2021-07-15	2021-07-16	A prospective non-randomized controlled study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus	A prospective cohort study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus	Systemic lupus erythematosus	Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome differentiation;Control Group:Western Medicine (glucocorticoid, hydroxychloroquine, methotrexate, azathioprine or cyclophosphamide);	Zhejiang Chinese Medical University	NULL	Pending	18	65	Female	Experimental group:264;Control Group:264;	N/A	China
5	ChiCTR1900022934	2019-06-20	2019-05-04	Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin	Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin	Systemic Lupus Erythematosus	Experimental group:Langchuangjing granule + Prednisone acetate tablets, Hydroxychloroquine;control group:Prednisone acetate tablets?Hydroxychloroquine;healthy control group:nothing;	Nanjing University of Chinese Medicine Affiliated Hospital	NULL	Pending			Both	Experimental group:20;control group:20;healthy control group:20;	Phase 1	China
6	ITMCTR1900002316	2019-06-20	2019-05-04	Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin	Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin	Systemic Lupus Erythematosus	healthy control group:nothing;control group:Prednisone acetate tablets\Hydroxychloroquine;Experimental group:Langchuangjing granule + Prednisone acetate tablets, Hydroxychloroquine;	Nanjing University of Chinese Medicine Affiliated Hospital	NULL	Pending			Both	healthy control group:20;control group:20;Experimental group:20;	Phase 1	China
7	ChiCTR1800020286	2019-02-01	2018-12-22	Clinical evaluation of the application of Langchuangjing granule in the treatment of systemic lupus erythematosus	Efficacy and safety of Langchuangjing granule in the treatment of systemic lupus erythematosus: a clinical evaluation	Systemic Lupus Erythematosus	Group 2:Langchuangjing granule + Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks.;Group 1:Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks.;	Nanjing University of Chinese Medicine Affiliated Hospital	NULL	Pending			Both	Group 2:40;Group 1:20;	I (Phase 1 study)	China
8	ChiCTR1800019308	2018-11-12	2018-11-04	Efficacy and tolerability of multitarget therapy with NHMX for systemic lupus erythematosus	Efficacy and tolerability of multitarget therapy with NHMX for systemic lupus erythematosus	systemic lupus erythematosus	NHMX:One kind of non-steroid anti-inflammatory drugs combines with hydroxychloroquine sulfate(=200mg/bid) and methotrexate(7.5-20mg/w), with addition of glucocorticoid (=0.5mg/kg·d) or cyclosporine (maintaining the drug concentration between 30-90ug/l);control:hydroxychloroquine sulfate(=200mg/bid) and methotrexate(7.5-20mg/w), with addition of glucocorticoid (=0.5mg/kg·d) or cyclosporine(maintaining the drug concentration between 30-90ug/l);	The Third Affiliated Hospital, Southern Medical University	NULL	Recruiting	18	65	Both	NHMX:75;control:75;		China
9	ChiCTR1800017540	2018-09-01	2018-08-03	A randomized controlled trial for the long-term outcomes of MMF on new onset SLE patients with high titers of anti-dsDNA antibody for reducing main organ involvement	A randomized controlled trial for the long-term outcomes of MMF on new onset SLE patients with high titers of anti-dsDNA antibody for reducing main organ involvement	systemic lupus erythematosus	1:Hydroxychloroquine (5mg/kg/day) plus prednisone (0.5mg/kg/day);2:Hydroxychloroquine (5mg/kg/day) plus prednisone (0.5mg/kg/day) plus Mycophenolate Mofetil 500mg bid;	Ruijin Hospital	NULL	Completed	18	65	Both	1:65;2:65;	Phase 4	China
10	NCT03030118 (ClinicalTrials.gov)	December 28, 2017	15/1/2017	Study of Anti-Malarials in Incomplete Lupus Erythematosus	Study of Anti-Malarials in Incomplete Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Hydroxychloroquine;Drug: Placebo Oral Capsule	Milton S. Hershey Medical Center	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Active, not recruiting	15 Years	49 Years	All	187	Phase 2	United States
11	NCT03122431 (ClinicalTrials.gov)	June 5, 2017	17/4/2017	Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases	Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects	Systemic Lupus Erythematosus (SLE);Juvenile SLE;Cutaneous Lupus	Drug: Thalidomide;Drug: Hydroxychloroquine reduced;Drug: standard dose of HCQ	University of Sao Paulo General Hospital	Fundação de Amparo à Pesquisa do Estado de São Paulo	Completed	5 Years	64 Years	All	93	Phase 4	Brazil
12	ChiCTR-INR-17011495	2017-05-25	2017-05-26	Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic sy	The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus	Primary mild to moderate systemic systemic lupus erythematosus	Immunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and week 24, the BILAG table, the SLE lesion index, and the SLE damage index were measured at 4 weeks, 12 weeks and 24 weeks. The levels of Th17, Treg and Th17 / Treg were measured.;Leflunomide treatment group:Leflunomide tablets 10m, 1 times / day, orally. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;Immunomodulatory treatment group and Leflunomide treatment group :0 weeks to give prednisone acetate tablets 0.5-1mg / kg.d (or patients can choose to take the same dose of methylprednisolone tablets), 4 weeks after the beginning of the dose by 2 weeks to reduce the regular dose of 10% Reduction to prednisone acetate tablets 10mg / day to maintain.;Immunomodulatory treatment group and Leflunomide treatment group:All patients without contraindications plus hydroxychloroquine tablets 0.2,2 / day, orally; and according to the condition plus calcium (800-1200mg / day), vitamin D (200-800IU / day) and other treatment.;	The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology	NULL	Recruiting			Both	Immunomodulatory treatment group:15;Leflunomide treatment group:15;Immunomodulatory treatment group and Leflunomide treatment group :30;Immunomodulatory treatment group and Leflunomide treatment group:30;		China
13	ChiCTR-ONC-15007547	2015-12-05	2015-12-04	Clinical theraputic effect of traditional Chinese medicine on systemic lupus erythematosus: a multicenter prospective cohort study	Study of the clinical theraputic effect of traditional Chinese medicine on systemic lupus erythematosus	systemic lupus erythematosus	The combination of Chinese and western group:Traditional Chinese medicine combined western medicine;Treating by Western Medicine group:Treating by Western medicine (sugar cortical hormone, hydroxychloroquine, and methotrexate, azathioprine, or cyclophosphamide);	Zhejiang Chinese Medical University	NULL	Recruiting	18	60	Both	The combination of Chinese and western group:264;Treating by Western Medicine group:264;		China
14	NCT02444728 (ClinicalTrials.gov)	July 2015	12/5/2015	Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE	Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus	Thrombocytopenia	Drug: Hydroxychloroquine;Drug: Cyclophosphamide;Drug: Azathioprine;Drug: Methylprednisolone	Chinese SLE Treatment And Research Group	Peking Union Medical College Hospital	Recruiting	18 Years	70 Years	All	220	Phase 3	China
15	EUCTR2014-005418-45-SE (EUCTR)	04/05/2015	18/03/2015	Are risk factors factors of pertaining to or involving the heart and blood vessels and markers characterized or caused by inflammation in Rheumatoid Arthritis (a chronic, systemic inflammatory disorder that primarily affects joints) and Systemic Lupus Erythematosus (systemic disease in which the body’s immune system mistakenly attacks healthy tissue)improved? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE)	Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE) - HCQCVDRASLE	Rheumatoid Arthritis and Systemic Lupus Erythematosus;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Plaquenil INN or Proposed INN: HYDROXYCHLOROQUINE	Christine Bengtsson	Solveig Wållberg-Jonsson	Not Recruiting			Female: yes Male: yes		Phase 2	Sweden
16	JPRN-UMIN000012478	2014/04/01	01/01/2014	Open label trial for efficacy and safety of Hydroxychloroquine for systemic lupus erythematosus	Open label trial for efficacy and safety of Hydroxychloroquine for systemic lupus erythematosus - Hydroxychloroquine for systemic lupus erythematosus	systemic lupus erythematosuscutaneous lupus erythematosus	Treatment with Hydroxychloroquine	Department of Internal Medicine, Teikyo University School of Medicine	NULL	Recruiting	Not applicable	Not applicable	Male and Female	10	Not selected	Japan
17	NCT01946880 (ClinicalTrials.gov)	November 20, 2013	13/9/2013	Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)	An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus;SLE	Drug: Mycophenolate Mofetil;Drug: Hydroxychloroquine or Chloroquine;Drug: Prednisone	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Terminated	18 Years	70 Years	All	102	Phase 2	United States
18	ChiCTR-TRC-12002419	2012-09-01	2012-08-01	The clinical research of metformin in achievienging the reduction in Flare of Mild/Moderate Active Lupus Patients	The clinical research of metformin in achievienging the reduction in Flare of Mild/Moderate Active Lupus Patients	systemic lupus erythematosus	1:Background treatment( - hydroxychloroquine );2:Background treatment( + hydroxychloroquine );3:Background treatment + hydroxychloroquine + Metformin;	Renji Hospital, Shanghai JiaoTong University School of Medicine	NULL	Completed	18	70	Both	1:60;2:60;3:60;		China
19	NCT01551069 (ClinicalTrials.gov)	March 2012	8/3/2012	Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion	A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion	Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus	Drug: hydroxychloroquine (Z0188);Drug: Placebo	Sanofi	NULL	Completed	18 Years	N/A	Both	103	Phase 3	Japan
20	NCT00413361 (ClinicalTrials.gov)	June 2007	18/12/2006	The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS	Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study	Systemic Lupus Erythematosus	Drug: versus hydroxychloroquine	Assistance Publique - Hôpitaux de Paris	Sanofi-Synthelabo	Completed	18 Years	N/A	Both	543	Phase 4	France

先頭へ

53. シェーグレン症候群

---

臨床試験数 : 305 /  薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-002470-32-NL (EUCTR)	12/12/2022	23/07/2021	NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patients	NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patients - NECESSITY	Primary Sjögren’s syndrome (pSS) MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: PLAQUENIL Product Name: Hydroxychloroquine INN or Proposed INN: Hydroxychloroquine Other descriptive name: HYDROXYCHLOROQUINE SULFATE Trade Name: Mycophenolate mofetil TEVA Product Name: mycophenolate mofetil INN or Proposed INN: Mycophenolate mofetil Other descriptive name: MYCOPHENOLATE MOFETIL Trade Name: Arava Product Name: Leflunomide INN or Proposed INN: LEFLUNOMIDE	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	Netherlands;Italy
2	NCT05016297 (ClinicalTrials.gov)	July 14, 2022	26/6/2021	Efficacy and Safety of Baricitinib in Sjogren's Syndrome	A Multi-center, Prospective, Open-label, Randomized Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients	Sjogren's Syndrome	Drug: Baricitinib;Drug: Hydroxychloroquine	Peking Union Medical College Hospital	Eli Lilly and Company	Recruiting	18 Years	75 Years	All	87	Phase 2	China
3	ChiCTR2200057578	2022-03-01	2022-03-15	Tofacitinib treatment in patients with primary Sjogren syndrome: a prospective pilot trial	Tofacitinib treatment in patients with primary Sjogren syndrome: a prospective pilot trial	Sjogren Syndrome	Control group:Same dose of hydroxychloroquine sulfate as before;Intervention group:Tofacitinib 5mg bid po+the same dose of hydroxychloroquine sulfate as before;	Ningbo Medical Center Lihuili Hospital	NULL	Pending	15	70	Both	Control group:60;Intervention group:60;	Phase 4	China
4	NCT05113004 (ClinicalTrials.gov)	January 20, 2022	2/11/2021	New Clinical End-points in Patients With Primary Sjögren's Syndrome	NEw Clinical Endpoints in Patients With Primary Sjögren's Syndrome (pSS): an Interventional Trial Based on stratifYing Patients	Primary Sjögren's Syndrome (pSS)	Drug: Hydroxychloroquine 400mg/d;Drug: Leflunomide 20mg/d;Drug: Mycophenolate mofetil 2000mg/d;Drug: Placebo of Hydroxychloroquine 400mg/d;Drug: Placebo of Leflunomide 20mg/d;Drug: Placebo of Mycophenolate mofetil 2000mg/d	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	N/A	All	300	Phase 2	France
5	EUCTR2019-002470-32-NO (EUCTR)	14/12/2021	26/08/2021	NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patients	NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patients - NECESSITY	Primary Sjögren’s syndrome (pSS) MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: PLAQUENIL Product Name: Hydroxychloroquine INN or Proposed INN: Hydroxychloroquine Other descriptive name: HYDROXYCHLOROQUINE SULFATE Trade Name: Mycophenolate mofetil TEVA Product Name: mycophenolate mofetil INN or Proposed INN: Mycophenolate mofetil Other descriptive name: MYCOPHENOLATE MOFETIL Trade Name: Arava Product Name: Leflunomide INN or Proposed INN: LEFLUNOMIDE	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	Netherlands;Norway;Italy
6	EUCTR2019-002470-32-IT (EUCTR)	05/10/2021	27/01/2022	Nuovi end-points clinici in pazienti con sindrome di Sjögren primaria (pSS): uno studio interventistico basato sulla stratificazione dei pazienti.	NEw Clinical End-points in patients with primary Sjögren's Syndrome (pSS): an Interventional Trial based on stratifYing patients - NECESSITY	Primary Sjögren's syndrome (pSS) MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Arava Product Name: Leflunomide Product Code: [Leflunomide] INN or Proposed INN: LEFLUNOMIDE Trade Name: Mycophenolate mofetil TEVA Product Name: mycophenolate mofetil Product Code: [mycophenolate mofetil] INN or Proposed INN: MICOFENOLATO MOFETILE Trade Name: PLAQUENIL Product Name: Hydroxychloroquine Product Code: [Hydroxychloroquine] INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE	ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	France;Greece;Spain;Norway;Netherlands;United Kingdom;Italy;Sweden
7	EUCTR2020-001933-11-NL (EUCTR)	10/06/2021	04/06/2021	Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome	Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome - RepurpSS-II study	Primary Sjogren Syndrome;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Leflunomide Product Name: Leflunomide Trade Name: Plaquenil Product Name: Hydroxychloroquine	University Medical Center Utrecht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	Netherlands
8	ChiCTR2000037989	2020-09-08	2020-09-08	Bushen Qingre Runzao decoction for primary Sjogren's syndrome: a randomized controlled trial	Bushen Qingre Runzao decoction for primary Sjogren's syndrome: a randomized controlled trial	Primary Sjogren's syndrome	Experimental group:Bushen Qingre Runzao Decoction 200ml bid po;Control group:Hydroxychloroquine sulfate tablets 200ml bid po;	China-Japan Friendship Hospital	NULL	Recruiting	18	75	Both	Experimental group:48;Control group:48;	N/A	China
9	ITMCTR2000003900	2020-09-08	2020-09-08	Bushen Qingre Runzao decoction for primary Sjogren's syndrome: a randomized controlled trial	Bushen Qingre Runzao decoction for primary Sjogren's syndrome: a randomized controlled trial	Primary Sjogren's syndrome	Control group:Hydroxychloroquine sulfate tablets 200ml bid po;Experimental group:Bushen Qingre Runzao Decoction 200ml bid po;	China-Japan Friendship Hospital	NULL	Recruiting	18	75	Both	Control group:48;Experimental group:48;	N/A	China
10	ChiCTR1900022696	2019-06-01	2019-04-22	A prospective, controlled, randomized, open-label, single-center study for eramyd in the treatment of active sjogren's syndrome	A prospective, controlled, randomized, open-label, single-center study for eramyd in the treatment of active sjogren's syndrome	Sjogren syndrome	experimental group :Iguratimod 25mg bid po;control group:hydroxychloroquine 0.2-0.4g/d+prednison0.2-0.5mg/kg.d;	Shanghai Tongji Hospital	NULL	Pending	18	70	Both	experimental group :60;control group:60;	Phase 4	China
11	ChiCTR1800014623	2018-02-01	2018-01-24	A prospective study on therapeutic effect of Mesenchymal stem cell on patients with primary Sjogren Syndrome	A prospective study on therapeutic effect of Mesenchymal stem cell on patients with primary Sjogren Syndrome	Sjogren Syndrome	stem cell group: Intravenous use mesenchymal stem cell ;hydroxychloroquine group:oral use hydroxychloroquine ;	Tongji Hospital of Tongji University	NULL	Recruiting			Both	stem cell group:20;hydroxychloroquine group:20;		China
12	EUCTR2014-003140-12-NL (EUCTR)	21/09/2015	26/08/2015	Leflunomide and Hydroxychloroquine combination therapy for primary Sjogren's Syndrome	Optimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome - LEF-HCQ combination therapy in pSS	Sjogren's Syndrome MedDRA version: 18.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 18.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;Classification code 10042846;Term: Syndrome Sjogren's;Classification code 10040765;Term: Sjogren's;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Leflunomide Mylan Product Name: Leflunomide mylan INN or Proposed INN: LEFLUNOMIDE Trade Name: Plaquenil Product Name: Plaquenil INN or Proposed INN: HYDROXYCHLOROQUINE	UMC Utrecht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no			Netherlands
13	ChiCTR-IPR-14005441	2014-01-01	2014-08-10	A double blind randomized study of Jiedu Tongluo Shengjin Decoction in treatment of primary Sjogren syndrome	A double blind randomized study of Jiedu Tongluo Shengjin Decoction in treatment of primary Sjogren syndrome	primary Sjogren syndrome	treatment group:hydroxychloroquine+Jiedu Tongluo Shengjin Decoction;	Yueyang Hospital of Integrative Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine	NULL	Recruiting	18	65	Both	treatment group:30;	I (Phase 1 study)	NULL
14	NCT01601028 (ClinicalTrials.gov)	July 2011	29/4/2012	Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome	Phase 3 Study of Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome	Autoimmune Diseases;Sjogren's Syndrome;Dry Eye	Drug: Hydroxychloroquine;Drug: Placebo	Seoul National University Hospital	NULL	Completed	19 Years	N/A	Both	39	Phase 3	Korea, Republic of
15	JPRN-UMIN000004477	2010/11/01	01/11/2010	Efficacy and safety of hydroxychloroquine for systemic/cutaneous lupus erythematosus or Sjogren's syndrome patients with annular erythema on the face and/or trunk	Efficacy and safety of hydroxychloroquine for systemic/cutaneous lupus erythematosus or Sjogren's syndrome patients with annular erythema on the face and/or trunk - Hydroxychloroquine for systemic/cutaneous lupus erythematosus or Sjogren's syndrome with annular erythema	Systemic/cutaneous lupus erythematosusSjogren's syndrome	Hydroxychloroquine 200 mg will be administrated once daily. If insufficient, dosage can be escalated to 400 mg twice daily, but not exceed 6.5 mg/kg/day.	Kanazawa University Graduate School of Medical Science	NULL	Complete: follow-up complete	20years-old	75years-old	Male and Female	10	Not applicable	Japan
16	NCT00632866 (ClinicalTrials.gov)	March 2008	29/2/2008	Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome	Randomized, Double-blind, Placebo-controlled Trial of Hydroxychloroquine in Primary Sjögren's Syndrome	Primary Sjögren's Syndrome	Drug: Hydroxychloroquine;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	Sanofi	Completed	18 Years	N/A	Both	120	Phase 3	France
17	EUCTR2007-005218-38-FR (EUCTR)	31/01/2008	20/11/2007	Essai prospectif Randomisé contre placebo en double aveugle de l’hydroxychloroQUine dans le traitement du syndrome de sJOgren primitif (JOQUER) - JOQUER	Essai prospectif Randomisé contre placebo en double aveugle de l’hydroxychloroQUine dans le traitement du syndrome de sJOgren primitif (JOQUER) - JOQUER	Syndrome de Sjögren primitif MedDRA version: 8.1;Level: PT;Classification code 10042846;Term: Syndrome Sjogren's	Trade Name: Plaquenil Product Name: Plaquenil INN or Proposed INN: Sulfate d'hydroxychloroquine	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
18	NCT00873496 (ClinicalTrials.gov)	January 2005	31/3/2009	Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients	Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients: a Prospective Sample Study.	Sjögren's Syndrome;Xerostomia	Drug: Hydroxychloroquine	Ege University	NULL	Completed	N/A	N/A	Female	30	N/A	Turkey

先頭へ

56. ベーチェット病

---

臨床試験数 : 81 /  薬物数 : 107 - (DrugBank : 30) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04022421 (ClinicalTrials.gov)	October 1, 2018	15/7/2019	Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis	The Efficacy of Hydroxychloroquine on Behcet's Disease Thrombotic Events Prevention	Behcet's Syndrome, Vascular Type	Drug: Hydroxychloroquine	Assiut University	NULL	Recruiting	18 Years	N/A	All	50	N/A	Egypt

63. 特発性血小板減少性紫斑病

---

臨床試験数 : 391 /  薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100045747	2020-12-01	2021-04-23	Efficacy and safety study of corticosteroids plus hydroxychloroquine in first-line treatment of patients with primary immune thrombocytopenia with positive antinuclear antibody	Efficacy and safety study of corticosteroids plus hydroxychloroquine in first-line treatment of patients with primary immune thrombocytopenia with positive antinuclear antibody	primary immune thrombocytopenia	Experimental group:hydroxychloroquine + Dexamethasone;Control group:Dexamethasone;	Jinshan Hospital, Fudan University	NULL	Recruiting	18		Both	Experimental group:51;Control group:51;	Phase 4	China

66. IgA腎症

---

臨床試験数 : 275 /  薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100045306	2021-04-10	2021-04-10	A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy	A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy	IgA nephropathy	Hydroxychloroquine group:Hydroxychloroquine and Kunxian capsule placebo;Kunxian capsule group:Kunxian capsule and Hydroxychloroquine placebo;Placebo group:Kunxian capsule and Hydroxychloroquine placebo;	Peking University First Hospital	NULL	Recruiting	18		Both	Hydroxychloroquine group:65;Kunxian capsule group:65;Placebo group:65;		China
2	ITMCTR2100004723	2021-04-10	2021-04-10	A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy	A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy	IgA nephropathy	Kunxian capsule group:Kunxian capsule and Hydroxychloroquine placebo;Hydroxychloroquine group:Hydroxychloroquine and Kunxian capsule placebo;Placebo group:Kunxian capsule and Hydroxychloroquine placebo;	Peking University First Hospital	NULL	Recruiting	18		Both	Kunxian capsule group:65;Hydroxychloroquine group:65;Placebo group:65;		China
3	ChiCTR2100052910	2021-04-01	2021-11-06	To investigate the efficacy and safety of hydroxychloroquine in IgA nephropathy based on PPK model	Efficacy and safety evaluation of hydroxychloroquine in the treatment of IgA nephropathy	IgA nephropathy	Experimental group:RAASi + hydroxychloroquine ;Cotrol group :RAASi+placebo ;	Department of Pharmacy, Drum Tower Hospital Affiliated to Nanjing University Medical School	NULL	Recruiting	18	75	Both	Experimental group:50;Cotrol group :50;	Phase 1	China
4	NCT02942381 (ClinicalTrials.gov)	September 13, 2016	14/10/2016	A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy		IgA Patients;Hydroxychloroquine	Drug: Hydroxychloroquine Sulfate;Drug: Placebo	Peking University First Hospital	NULL	Completed	18 Years	75 Years	All	60	Phase 2	China
5	NCT02765594 (ClinicalTrials.gov)	June 2016	30/4/2016	Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy	Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study	Primary IgA Nephropathy	Drug: Hydroxychloroquine Sulfate;Drug: Valsartan	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	60 Years	All	98	Phase 4	China
6	NCT02351752 (ClinicalTrials.gov)	January 2015	27/1/2015	Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study	Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease	Primary IgA Nephropathy	Drug: Hydroxychloroquine Sulfate	LLiu	NULL	Completed	18 Years	75 Years	Both	20	Phase 4	China

先頭へ

84. サルコイドーシス

---

臨床試験数 : 149 /  薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05247554 (ClinicalTrials.gov)	March 1, 2022	9/2/2022	Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis	Randomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticosteroid Therapy in Pulmonary Sarcoidosis	Pulmonary Sarcoidosis	Drug: Hydroxychloroquine + low-dose prednisone;Drug: Prednisone	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	18 Years	80 Years	All	200	Phase 3	NULL
2	NCT02200146 (ClinicalTrials.gov)	March 2009	10/7/2014	Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).	Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial.	Pulmonary Sarcoidosis	Drug: Prednisone;Drug: Hydroxychloroquine + Prednisone	University of Milano Bicocca	Agenzia Italiana del Farmaco	Completed	18 Years	70 Years	Both	94	Phase 3	Italy
3	EUCTR2008-001340-39-IT (EUCTR)	30/06/2008	13/06/2008	Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS	Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS	Pulmonary Sarcoidosis	Trade Name: PLAQUENIL*25CPR RIV 200MG INN or Proposed INN: Hydroxychloroquine Trade Name: DELTACORTENE*10CPR 25MG INN or Proposed INN: Prednisone	UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy

89. リンパ脈管筋腫症

---

臨床試験数 : 38 /  薬物数 : 38 - (DrugBank : 15) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 118

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01687179 (ClinicalTrials.gov)	September 2012	2/8/2012	Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis	Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus	Lymphangioleiomyomatosis	Drug: Sirolimus and Hydroxychloroquine 200 mg;Drug: Sirolimus and Hydroxychloroquine 400 mg	Brigham and Women's Hospital	National Heart, Lung, and Blood Institute (NHLBI)	Completed	18 Years	85 Years	Female	14	Phase 1	United States

90. 網膜色素変性症

---

臨床試験数 : 147 /  薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04120883 (ClinicalTrials.gov)	February 25, 2020	8/10/2019	Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)	Oral Hydroxychloroquine for Retinitis Pigmentosa Caused by P23H-RHO (Substitution of Proline to Histidine at Codon 23 of the Rhodopsin Protein)	Retinitis Pigmentosa	Drug: Hydroxychloroquine lower dose;Drug: Hydroxychloroquine higher dose	University of Michigan	Cures Within Reach	Recruiting	18 Years	N/A	All	12	Phase 1/Phase 2	United States

96. クローン病

---

臨床試験数 : 2,442 /  薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01783106 (ClinicalTrials.gov)	February 1, 2014	31/1/2013	Antibiotics and Hydroxychloroquine in Crohn's	A Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and Hydroxychloroquine) With Standard Therapy (Budesonide) in the Treatment of Active Crohn's Disease	Crohn's Disease	Drug: Ciprofloxacin;Drug: Doxycycline;Drug: Hydroxychloroquine;Drug: Budesonide	Royal Liverpool University Hospital	National Association for Colitis and Crohn's Disease;National Institute for Health Research, United Kingdom	Completed	18 Years	N/A	All	59	Phase 2	United Kingdom
2	EUCTR2008-001137-99-GB (EUCTR)	28/04/2009	27/11/2008	CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease	CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease	Crohn's Disease MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders	Product Name: Ciprofloxacin Product Code: PL 20532/0012 INN or Proposed INN: Ciprofloxacin hydrochloride Product Name: Budesonide Product Code: PL 17901/0122 INN or Proposed INN: Budesonide Other descriptive name: Entocort CR Trade Name: DOXYCYCLINE Product Name: DOXYCYCLINE INN or Proposed INN: DOXYCYCLINE HYCLATE Other descriptive name: DOXYCYCLINE Trade Name: HYDROXYCHLOROQUINE Product Name: HYDROXYCHLOROQUINE SULPHATE INN or Proposed INN: HYDROXYCHLOROQUINE SULPHATE Other descriptive name: PLAQUENIL	Royal Liverpool & Broadgreen University Hospitals Trust	University of Liverpool	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom

97. 潰瘍性大腸炎

---

臨床試験数 : 2,630 /  薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05119140 (ClinicalTrials.gov)	June 10, 2022	20/10/2021	HCQ for Non Europeans With Mild to Severe UC	Administration of Hydroxychloroquine (Plaquenil) to Individuals of Non-European Ancestry for the Treatment of Mild to Severe Ulcerative Colitis.	Ulcerative Colitis (Disorder)	Drug: Hydroxychloroquine;Drug: Mesalamine	Icahn School of Medicine at Mount Sinai	Crohn's and Colitis Foundation	Recruiting	18 Years	N/A	All	20	Phase 1/Phase 2	United States

107. 若年性特発性関節炎

---

臨床試験数 : 447 /  薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-003260-20-NL (EUCTR)	04/05/2016	17/11/2015	CHAMP Trial: comparing monotherapy and polytherapy treatment strategies in newly diagnosed juvenile idiopathic arthritis.	CHAMP: Children with Arthritis: Monotherapy or Polytherapy. A multicentre, single-blinded, randomized treat to target, one-year follow-up clinical trial in patients with recent onset Juvenile Idiopathic Arthritis (JIA). - CHAMP	Juvenile idiopathic arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Methotrexate INN or Proposed INN: METHOTREXATE Other descriptive name: METHOTREXATE Trade Name: sulfasalazine Product Name: Sulfasalazine INN or Proposed INN: SULFASALAZINE Other descriptive name: SULFASALAZINE Trade Name: Hydroxychloroquine Product Name: Hydroxychloroquine INN or Proposed INN: HYDROXYCHLOROQUINE Other descriptive name: HYDROXYCHLOROQUINE	Leiden University Medical Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 4	Netherlands

218. アルポート症候群

---

臨床試験数 : 30 /  薬物数 : 36 - (DrugBank : 15) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 46

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04937907 (ClinicalTrials.gov)	September 8, 2021	17/6/2021	Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)	Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)	Alport Syndrome, X-Linked	Drug: Hydroxychloroquine Sulfate 100 milligram (mg) Tab;Drug: Benazepril hydrochloride 10 milligram (mg) Tab	Shanghai Children's Hospital	NULL	Recruiting	3 Years	18 Years	All	50	Phase 2	China
2	ChiCTR2000036799	2020-10-01	2020-08-25	Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome	Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome	Alport Syndrome	experimental group:Hydroxychloroquine + Benazepril Hydrochloridec;control group:placebo + benazepril hydrochloride;	Shanghai Children's Hospital	NULL	Pending	0	18	Both	experimental group:25;control group:25;	N/A	China

222. 一次性ネフローゼ症候群

---

臨床試験数 : 310 /  薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1900021757	2019-03-01	2019-03-08	A randomized controlled trial for hydroxychloroquine sulfate in the treatment of idiopathic membranous nephropathy	The efficacy and safety of hydroxychloroquine sulfate in idiopathic membranous nephropathy: A randomized, controlled, Single-center clinical trial	Idiopathic Membranous Nephropathy	Group 1:Supportive treatment+Perindopril 8 mg/day;Group 2:Supportive treatment+Perindopril 8 mg/day+hydroxychloroquine sulfate (200mg 2/d);Group 3:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml);Group 4:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml)+hydroxychloroquine sulfate (200mg 2/d);	Nephrology Division, First Hospital Affiliated to Army Medical University	NULL	Recruiting	18	60	Both	Group 1:55;Group 2:55;Group 3:55;Group 4:55;	Phase 4	China
2	ChiCTR2100045947	2016-04-08	2021-04-30	Effects of hydroxychloroquine on proteinuria of primary membranous nephropathy	Effects of hydroxychloroquine on proteinuria of primary membranous nephropathy	primary membranous nephropathy	HCQ group :hydroxychloroquine;	Renal Division, Peking University First Hospital	NULL	Completed			Both	HCQ group :22;	N/A	China

224. 紫斑病性腎炎

---

臨床試験数 : 16 /  薬物数 : 43 - (DrugBank : 21) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 58

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200057905	2022-04-01	2022-03-21	A prospective, open, randomized controlled study of hydroxychloroquine sulfate in the treatment of adult Henoch Schonlein purpura nephritis	A prospective, open, randomized controlled study of hydroxychloroquine sulfate in the treatment of adult Henoch Schonlein purpura nephritis	Henoch Schonlein purpura nephritis	Experimental group:Hydroxychloroquine sulfate;Control group:Conventional therapy;	Daping Hospital, Army Medical University	NULL	Recruiting	18		Both	Experimental group:42;Control group:42;	Phase 4	China
2	ChiCTR2000040625	2021-01-01	2020-12-04	Therapeutic effect of hydroxychloroquine on children Henoch-Schonlein purpura nephritis	Therapeutic effect of hydroxychloroquine on children Henoch-Schonlein purpura nephritis	Henoch-Schonlein purpura nephritis	A:Basic treatment + hydroxychloroquine (5mg/kg.d, taken orally in 2 doses);B:Basic treatment;	Shengjing Hospital of China Medical University	NULL	Pending	3	14	Both	A:20;B:20;	N/A	China

234. ペルオキシソーム病（副腎白質ジストロフィーを除く。）

---

臨床試験数 : 39 /  薬物数 : 35 - (DrugBank : 12) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03856866 (ClinicalTrials.gov)	January 11, 2019	5/11/2018	Hydroxychloroquine Administration for Reduction of Pexophagy	Hydroxychloroquine Administration for Reduction of Pexophagy	Zellweger Syndrome;Peroxisome Biogenesis Disorders	Drug: Hydroxychloroquine;Drug: Placebo	The Hospital for Sick Children	NULL	Recruiting	6 Months	40 Years	All	5	Phase 2	Canada

254. ポルフィリン症

---

臨床試験数 : 72 /  薬物数 : 53 - (DrugBank : 16) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01573754 (ClinicalTrials.gov)	March 21, 2006	5/4/2012	Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda	A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435	Porphyria Cutanea Tarda	Drug: Hydroxychloroquine;Procedure: Phlebotomy	The University of Texas Medical Branch, Galveston	NULL	Completed	18 Years	100 Years	All	48	Phase 2	United States

271. 強直性脊椎炎

---

臨床試験数 : 574 /  薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04077957 (ClinicalTrials.gov)	October 7, 2019	1/9/2019	Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs	Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study	Ankylosing Spondylitis;Spondyloarthritis	Drug: Methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine;Drug: Etanercept (50mg per week, for 4 weeks);Drug: Etanercept (50mg per week, for 2 weeks);Drug: Etanercept (50mg per week)	Nanfang Hospital of Southern Medical University	NULL	Not yet recruiting	18 Years	50 Years	All	100	Phase 4	China

298. 遺伝性膵炎

---

臨床試験数 : 95 /  薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03283566 (ClinicalTrials.gov)	October 3, 2017	13/9/2017	Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT	Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing Total Pancreatectomy and Autologous Islet Transplantation: A Clinical, Molecular, and Genomic Study	Chronic Pancreatitis;Insulin Dependent Diabetes	Drug: Hydroxychloroquine;Drug: Placebo	The Cleveland Clinic	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute);Stanford University	Completed	18 Years	65 Years	All	9	Phase 2	United States

299. 嚢胞性線維症

---

臨床試験数 : 1,695 /  薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00311883 (ClinicalTrials.gov)	March 2006	4/4/2006	Hydroxychloroquine in Cystic Fibrosis	Phase 1 Study of Hydroxychloroquine in Cystic Fibrosis	Cystic Fibrosis	Drug: hydroxychloroquine	Vanderbilt University	NULL	Completed	16 Years	N/A	Both	20	Phase 1	United States

先頭へ